EE200200033A - Uued ühendid - Google Patents

Uued ühendid

Info

Publication number
EE200200033A
EE200200033A EEP200200033A EEP200200033A EE200200033A EE 200200033 A EE200200033 A EE 200200033A EE P200200033 A EEP200200033 A EE P200200033A EE P200200033 A EEP200200033 A EE P200200033A EE 200200033 A EE200200033 A EE 200200033A
Authority
EE
Estonia
Prior art keywords
new compounds
compounds
new
Prior art date
Application number
EEP200200033A
Other languages
English (en)
Inventor
Berge Odd-Geir
Claesson Alf
Swahn Britt-Marie
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9902762A external-priority patent/SE9902762D0/xx
Priority claimed from SE0000263A external-priority patent/SE0000263D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200033A publication Critical patent/EE200200033A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
EEP200200033A 1999-07-21 2000-07-20 Uued ühendid EE200200033A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9902762A SE9902762D0 (sv) 1999-07-21 1999-07-21 New compounds
SE0000263A SE0000263D0 (sv) 2000-01-27 2000-01-27 New compounds
PCT/SE2000/001506 WO2001005790A1 (en) 1999-07-21 2000-07-20 New compounds

Publications (1)

Publication Number Publication Date
EE200200033A true EE200200033A (et) 2003-02-17

Family

ID=26654970

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200033A EE200200033A (et) 1999-07-21 2000-07-20 Uued ühendid

Country Status (28)

Country Link
US (2) US6774132B1 (et)
EP (2) EP1202994B1 (et)
JP (1) JP2003505388A (et)
KR (1) KR20020033738A (et)
CN (1) CN1361779A (et)
AR (1) AR029174A1 (et)
AT (1) ATE264330T1 (et)
AU (1) AU775426B2 (et)
BG (1) BG106310A (et)
BR (1) BR0012590A (et)
CA (1) CA2378202A1 (et)
CZ (1) CZ2002203A3 (et)
DE (1) DE60009915T2 (et)
DK (1) DK1202994T3 (et)
EE (1) EE200200033A (et)
ES (1) ES2218191T3 (et)
HU (1) HUP0203548A3 (et)
IL (1) IL147217A0 (et)
IS (1) IS6239A (et)
MX (1) MXPA02000670A (et)
NO (1) NO20020283L (et)
NZ (1) NZ516452A (et)
PL (1) PL352911A1 (et)
PT (1) PT1202994E (et)
RU (1) RU2002104496A (et)
SK (1) SK822002A3 (et)
TR (1) TR200200118T2 (et)
WO (1) WO2001005790A1 (et)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774132B1 (en) 1999-07-21 2004-08-10 Astrazeneca Ab Spirooxindole derivatives that act as analgesics
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2006012226A2 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
CA2584502A1 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
EP1855686A1 (en) * 2005-03-01 2007-11-21 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
DE102005044813A1 (de) * 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044814A1 (de) * 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
EP1911753A1 (en) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
WO2007091948A2 (en) * 2006-02-07 2007-08-16 Astrazeneca Ab Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1
EP1984374A1 (en) * 2006-02-07 2008-10-29 AstraZeneca AB Use of spiro ý imidazolidine-4, 3'-indole¨2, 2', 5' (1h) triones for treatment of conditions associated with vanilloid receptor 1
AR059265A1 (es) 2006-02-07 2008-03-19 Astrazeneca Ab Compuestos espiro condensados con actividad inhibitoria en el receptor vaniloide1 (vr1)
US7495007B2 (en) * 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
ES2350504T3 (es) * 2006-03-13 2011-01-24 F. Hoffmann-La Roche Ag Derivados de espiroindolinona.
US20070213341A1 (en) * 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
CA2644758A1 (en) * 2006-03-13 2007-09-20 F. Hoffmann-La Roche Ag Spiroindolinone derivatives
CL2007002950A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Uso de compuestos derivados de espiro-oxindol en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer
US7776875B2 (en) * 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
RU2011119626A (ru) 2008-10-17 2012-11-27 Ксенон Фармасьютикалз Инк. Спирооксиндольные соединения и их применение в качестве терапевтичеких средств
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
RU2015103694A (ru) 2009-10-14 2015-06-27 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) * 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
CN102946859B (zh) 2010-02-26 2016-03-02 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
WO2011149950A2 (en) 2010-05-24 2011-12-01 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
US20130267699A1 (en) 2011-06-24 2013-10-10 California Institute Of Technology Quaternary heteroatom containing compounds
WO2014085795A1 (en) 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
WO2015116904A1 (en) 2014-02-03 2015-08-06 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
SI3207043T1 (sl) 2014-10-14 2019-04-30 Vitae Pharmaceuticals, Inc. Dihidropirolopiridinovi inhibitorji za ROR-gama
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US10421696B2 (en) * 2014-12-18 2019-09-24 California Institute Of Technology Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
WO2017156239A1 (en) 2016-03-11 2017-09-14 California Institute Of Technology Compositions and methods for acylating lactams
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3592747A1 (en) 2017-03-10 2020-01-15 Council of Scientific and Industrial Research Spirooxindole compounds as gsk3 inhibitors and process for preparation thereof
MX2019013557A (es) * 2017-05-15 2022-01-27 Recurium Ip Holdings Llc Compuestos biciclo[1.1.1]pentilo sustituidos y uso de los mismos para el tratamiento del dolor y fiebre.
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN111225914B (zh) 2017-07-24 2022-10-11 生命医药有限责任公司 RORγ的抑制剂
ES2951874T3 (es) * 2017-09-05 2023-10-25 Neumora Therapeutics Inc Antagonistas del receptor de vasopresina y productos y métodos relacionados con los mismos
EP3699173A1 (en) 2018-10-18 2020-08-26 California Institute of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
CN115772171A (zh) * 2021-09-09 2023-03-10 沈阳药科大学 一价金催化的螺[吲哚啉-3,3’-哌啶]骨架的合成方法
CN115785104A (zh) * 2021-09-09 2023-03-14 沈阳药科大学 一种一价金催化的螺[吲哚啉-3,3’-吡咯烷]衍生物的合成方法
CN116375685B (zh) * 2023-03-29 2023-12-12 沈阳药科大学 一种法舒地尔衍生物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5089376A (et) 1973-12-19 1975-07-17
JPS54109983A (en) * 1978-02-13 1979-08-29 Sumitomo Chem Co Ltd Novel spiroamine derivative and its preparation
US4632923A (en) 1984-08-15 1986-12-30 Schering Corporation Substituted hetero spiro pyridine derivatives as anti-allergy and anti-inflammatory agents
DE3481418D1 (de) 1983-12-14 1990-04-05 Schering Corp Substituierte spiropyridinderivate, diese enthaltende pharmazeutische zubereitungen, verfahren zu ihrer herstellung und zubereitungen.
US4652564A (en) 1983-12-14 1987-03-24 Schering Corporation Substituted spiro pyridine derivatives as anti-allergy and antiinflammatory agents
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5206240A (en) * 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
US5091387A (en) 1990-03-02 1992-02-25 Merck & Co., Inc. Spirocyclic oxytocin antagonists
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2689509B1 (fr) 1992-04-01 1994-06-03 Adir Nouveaux derives spiraniques du 3-amino chromane, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
DE69412067T2 (de) * 1993-01-28 1999-03-25 Merck & Co Inc Substituierte spiro-azaringen als tachykinine rezeptor antagonisten
US5817756A (en) * 1993-09-09 1998-10-06 Scios Inc. Pseudo- and non-peptide bradykinin receptor antagonists
US5763471A (en) 1994-04-07 1998-06-09 Cemaf Melatoninergic agonist spiro indolepyrrolidine! derivatives, process for their preparation and their use as medicinal products
AU7169696A (en) * 1995-09-26 1997-04-17 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
US6156783A (en) 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
US6774132B1 (en) 1999-07-21 2004-08-10 Astrazeneca Ab Spirooxindole derivatives that act as analgesics

Also Published As

Publication number Publication date
BR0012590A (pt) 2002-04-09
IL147217A0 (en) 2002-11-10
AU6330900A (en) 2001-02-05
EP1426375A2 (en) 2004-06-09
AR029174A1 (es) 2003-06-18
CA2378202A1 (en) 2001-01-25
JP2003505388A (ja) 2003-02-12
RU2002104496A (ru) 2003-09-27
IS6239A (is) 2002-01-18
PT1202994E (pt) 2004-08-31
KR20020033738A (ko) 2002-05-07
EP1426375A3 (en) 2004-12-15
CZ2002203A3 (cs) 2002-08-14
CN1361779A (zh) 2002-07-31
DK1202994T3 (da) 2004-08-02
DE60009915T2 (de) 2005-04-07
NZ516452A (en) 2004-06-25
AU775426B2 (en) 2004-07-29
US20040087800A1 (en) 2004-05-06
NO20020283D0 (no) 2002-01-18
NO20020283L (no) 2002-03-13
ATE264330T1 (de) 2004-04-15
ES2218191T3 (es) 2004-11-16
HUP0203548A2 (hu) 2003-02-28
US6774132B1 (en) 2004-08-10
PL352911A1 (en) 2003-09-22
HUP0203548A3 (en) 2003-04-28
BG106310A (bg) 2002-12-29
WO2001005790A1 (en) 2001-01-25
MXPA02000670A (es) 2002-07-02
EP1202994B1 (en) 2004-04-14
SK822002A3 (en) 2002-09-10
EP1202994A1 (en) 2002-05-08
DE60009915D1 (de) 2004-05-19
TR200200118T2 (tr) 2002-12-23

Similar Documents

Publication Publication Date Title
IS6024A (is) Ný efnasambönd
PT1202994E (pt) Novos compostos
NO20016115D0 (no) Substituerte heterocykelkondenserte gamma-karboliner
PT1224180E (pt) Azois substituidos
EE200200224A (et) Uudsed ühendid
IS6139A (is) Ný efnasambönd
DE59909346D1 (de) Zylinderkopfdichtung
NO20013769D0 (no) Kalsilytiske forbindelser
IS6141A (is) Ný efnasambönd
NO20020466D0 (no) Kalsilytiske forbindelser
NO20014262D0 (no) Tiazoloindolinon-forbindelser
NO20022927D0 (no) Substituerte pyrrazoler
NO994783L (no) Reduksjonsmiddelagglomerat
ATA121799A (de) Ausbeulgerät
DK1200423T3 (da) Substituerede pehnyluraciler
ATA107599A (de) Heizwasserbereiter
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
SE9900086D0 (sv) New compounds
SE9902762D0 (sv) New compounds
SE9904420D0 (sv) New compounds
SE9900071D0 (sv) New compounds
SE9904422D0 (sv) New compounds
SE9904228D0 (sv) New compounds
SE9904418D0 (sv) New compounds
AT500658A3 (de) Isolierplatte